Mortality Reduction and Cardiovascular Protection with Semaglutide

Mortality Reduction Evidence

The American Diabetes Association recommends semaglutide as it significantly reduces all-cause mortality and cardiovascular death in patients with type 2 diabetes, with a 22% reduction in cardiovascular mortality and a 26% reduction in the composite outcome of cardiovascular death, nonfatal MI, or nonfatal stroke 1, 2, 3, 4
The European Association for the Study of Diabetes suggests that semaglutide provides a mean increase of 1.7 life-years free of cardiovascular disease, with greater benefits in patients with established cardiovascular disease 1, 3, 4

The American Heart Association notes that semaglutide extends life through multiple cardioprotective mechanisms beyond glucose control, including improved myocardial substrate utilization and reduced myocardial ischemia injury, anti-inflammatory and anti-atherosclerotic effects, reduced systemic and pulmonary vascular resistance, and improved lipid profiles and blood pressure reduction 1, 3, 4
The American College of Cardiology recommends semaglutide due to its cardioprotective effects, which are supported by a 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease 1, 3, 4

The International Diabetes Federation suggests that semaglutide is particularly beneficial for patients with type 2 diabetes and established cardiovascular disease, with a 26% reduction in major adverse cardiovascular events 1, 3, 4
The American Association of Clinical Endocrinologists notes that semaglutide also provides benefits for patients with obesity and cardiovascular disease, even without diabetes, with a 20% reduction in cardiovascular death, nonfatal MI, or nonfatal stroke 6